



CLART® STIs A

**DETECTION AND GENETIC IDENTIFICATION OF PATHOGENS CAUSING SEXUALLY TRANSMITTED
INFECTIONS, STIs**

FOR *IN VITRO* DIAGNOSIS

CLART® STIs A

CLART®, *CLART-Strip®*, *CAR®*, *SAICLART®* and *AUTOCLART®* are registered Trademarks of GENOMICA.

For more information, please refer to the web site www.genomica.com

Only *Chlamydia trachomatis* diagnostic has been assented by the NB 0318.
CE for other microorganisms



GENOMICA, S.A.U.
Parque Empresarial Alvento, Edificio B
Calle Vía de los Poblados, 1 – 1ª planta
28033 Madrid, Spain
www.genomica.com

Version 6
March 2016

TABLE OF CONTENTS:

- 1. GLOSSARY**
- 2. PROTOCOL DESCRIPTION**
- 3. KIT COMPONENTS AND STORAGE**
 - 3.1. Extraction and purification reagents.**
 - 3.2. Amplification reagents**
 - 3.2. Visualization reagents**
 - 3.3. Other components**
- 4. MATERIALS REQUIRED BUT NOT PROVIDED**
 - 4.1. Reagents and materials**
 - 4.2. Equipment**
- 5. RECOMMENDATIONS AND HANDLING PROCEDURES**
 - 5.1. General recommendations**
 - 5.2. Precautions for the extraction and addition of extracted material to the amplification tube**
 - 5.2. Precautions for visualization**
- 6. SAMPLES**
- 7. WORKING PROTOCOL**
 - 7.1 Extraction of genetic material**
 - 7.1.1. Manual extraction of genetic material**
 - 7.1.2. Automatic extraction of genetic material**
 - 7.2. Amplification reaction**
 - 7.3. Visualization of the amplified product**
 - 7.3.1. Manual visualization**
 - 7.3.2. autoclart® visualization**
- 8. READING OF THE RESULTS**
- 9. INTERPRETATION OF THE RESULTS**
- 10. TECHNICAL AND OPERATIONAL SPECIFICATIONS**
- 11. BIBLIOGRAPHY**

1. GLOSSARY



Attention, see instructions for use




Expiration date




In vitro diagnostic medical device




Batch



Store at room temperature



Store at 2°C to 8°C



Store at –30°C to –18°C

2. PROTOCOL DESCRIPTION

CLART® STIs A detects the presence microorganisms causing sexually transmitted infections in clinical samples (urine and swabs).

The microorganisms detected are detailed in the list below:

- *Chlamydia trachomatis*: It will distinguish between the two serotypes groups:
 - Producers of lymphogranuloma venereum (LGV), include serotypes L1, L2 and L3.
 - Non -producers of lymphogranuloma venereum (NLGV), include serotypes D-K.It will include a generic detection of *Chlamydia trachomatis* for those cases in which the serotype is not achieve.
- *Neisseria gonorrhoeae*
- *Mycoplasma genitalium*
- *Trichomonas vaginalis*

Detection is carried out by the specific **amplification** of each microorganism in the sample, originating a variable fragment between **100 and 300 base pairs**.

To avoid false negatives the tube contains an amplification internal control which ensure the correct working of the tube, and a genomic DNA extraction control from the sample which guarantee that genetic material has been isolated during the extraction process.

The detection of the product amplified by PCR is carried out by means of a low-density microarray platform: CLART® (Clinical Arrays Technology). The platform is based on a very simple principle, but at the same time cost effective. It consists of a microarray printed at the bottom of a microtiter plate well, which simplifies the entire hybridization and visualization process when compared to classic microarray systems. Figure 1 displays a CLART-Strip® or CS of 8 wells.



Figure 1. CLART-Strip®-CS platform in the form of an 8-well strip.

The **CLART® STIs A** detection system is based on the precipitation of an insoluble product in those microarray areas in which hybridization of amplification products with specific probes takes place. During PCR, amplified products are labelled with biotin. After amplification, these products are hybridized with their respective specific complementary probes that are immobilised in specific and well-known microarray areas. Afterwards they are then incubated with a streptavidine-

peroxidase conjugate. The conjugate is bound through streptavidine with the biotin present in the amplified products (which are bound to their specific probes) and the peroxidase activity prompts the appearance of a non-soluble product in the presence of the o-dianisidine substrate, which precipitates on the microarray areas where hybridization occurs (Figure 2).




Figure 2: Diagram of the visualization method. Probes, immobilized on the surface, capture their complementary biotin-labelled amplified products. With the help of biotin, they bind to the conjugate, in this case streptavidine-HRP (*HorseRadish Peroxidase*). The o-dianisidine substrate, by the action of the HRP, produces a precipitate on the area where hybridization occurs.

3.-KIT COMPONENTS AND STORAGE

The **CLART® STIs A** kit contains reagents enough for performing 16 or 48 clinical samples analysis. The reagents included in the kit have been grouped into various packages, depending on the temperature at which they should be stored. When storage recommendations are observed, all reagents should remain stable until kit's expiration date.

3.1 Extraction and purification reagents.

- Extraction and Purification reagents are delivered to users at 4°C or room temperature.

Components:

- Purification columns adapted to 2 ml tubes
- 2 ml Collection Tubes
- Buffer T1
- Buffer B3
- Buffer B5
- Buffer BW
- Buffer BE
- Proteinase K, lyophilized (keep at -20°C when resuspended)
- Buffer PB

3.2. Amplification reagents

They are shipped and should be stored at -20°C.

- **Amplification tubes** (white tube). Ready-to-use. They contain 45 µL of reaction mixture. Thaw on ice the exact number of amplification tubes that will be used and keep the rest at -20°C.

This tube allows the amplification of *Chlamydia trachomatis* LGV, *Chlamydia trachomatis* NLGV, *Chlamydia trachomatis* generic, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis*. It also includes the amplification of an amplification control and an extraction control.

The kit package includes a self-adhesive and irreversible temperature indicator; the appearance of a reddish colour on the visualization window indicates that, at a certain moment, products have exceeded the storage temperature of -20°C and they should not be used.

3.3. Visualization reagents

The visualization kit is shipped and should be stored at 4°C.

WARNING: Once received, the CLART-Strip® (CS) should be stored at room temperature.

- **CS strips** (including all specific probes). They are provided in a sealed thermal envelope. **Store it closed at room temperature (25°C max.), protected from direct light.**
- **SH** (Hybridization Solution). **Store at 4°C.**
- **DC** (Conjugate Diluent). **Store at 4°C.**
- **CJ** (Conjugate). **Store at 4°C.** Centrifuge once before use.
- **RE** (Development Solution). **Store at 4°C and protected from light.**
- **TL** (Wash Buffer). **Store at 4°C.**
- **Adaptor and lid for 8-well strips.**

3.4 Other components

For the capture and subsequent processing of the image, a reader unit, running a tailor made software and, the plate adaptor, are required:

- **CAR®** (CLINICAL ARRAY READER): it allows for the automatic reading and interpretation of up to 12 CS, i.e., up to a maximum of 96 samples. It is manufactured and distributed by GENOMICA, to be used exclusively with its diagnostic kits.
- **SAICLART®**: software developed and validated by GENOMICA for image processing.
- kit **CLART® STIs A specific software** designed and validated by GENOMICA



Figure 3. CAR® (CLINICAL ARRAY READER)

4.-MATERIALS REQUIRED BUT NOT PROVIDED

Below you can find a list of all materials required but not provided.

4.1. Reagents and materials

- Distilled water.
- Disposable gloves.
- Filter tips or positive displacement pipettes.
- Crushed ice container.
- 1.5 mL autoclaved Eppendorf type tubes.
- 1.5 mL tube grids.
- 0.5 mL/0.2 mL tube holder.
- Saline solution 0.9% NaCl

4.2. Equipment

- autoclart® (Figure 4) The following equipment is needed for the automatic visualization phase. It enables the automatic visualization of up to 12 CS that means a total amount of 96 samples.




Figure 4. autoclart®

- Microcentrifuge.
- Thermocycler.
- Laminar flow chamber for the extraction laboratory.
- Three adjustable micropipettes ranging from 1-20 μL , 20-200 μL , and 200-1000 μL for the extraction laboratory.
- One adjustable micropipette ranging from 1-20 μL , to add the genetic material to the amplification tubes.
- Three adjustable micropipettes ranging from 1-20 μL , 20-200 μL , and 200-1000 μL for the visualization laboratory.
- Thermoblock with plate adapter, lid and adjustable shaking at 25°C, 30°C y 56°C. Compatible with 96-well plates.
- Vortex.
- Vacuum system.

5.-RECOMMENDATIONS AND HANDLING PROCEDURES

Read carefully before starting the assay in order to avoid contamination! Read carefully before beginning the technique

5.1. General recommendations

1. This assay should be performed in two physically separated areas, in order to avoid sample contamination with the previously amplified product. Separate working materials should be available in each area (pipettes, tips, tubes, grids, gloves, etc.) which should never be used outside these areas.

1. Pre-PCR area: DNA extraction, sample preparation and addition of the extracted material to the amplification tubes are performed in this area. Sample manipulation must be carried out within a biosafety cabinet (BSC).

2. Post-PCR area: Amplification and visualization of the amplified product are carried out in this area. The material of this area should never come into contact with the material of the extraction area. Avoid entering the pre-PCR area after having worked in the visualization area.

2. Always use gloves. It is recommended to change gloves quite frequently, and it is mandatory to change gloves before start working in each of the aforementioned areas. New gloves must always be used when DNA is added to the amplification tubes.

3. Clean working areas (laboratory cabinets, hoods, grids, pipettes) thoroughly with a 10% diluted bleach solution **after every sample batch processing**; it is mandatory to disinfect all working areas in case of contamination. For thermocyclers and thermomixers, it is advised to clean them before and after used, in these same conditions.

4. Always use filter tips and positive displacement pipettes to avoid contamination due to micropipettes. Different sets of pipettes should be used in each area.

5. Use disposable and autoclaved laboratory material.

6. Never mix reagents from two different vials, even if they belong to the same lot.

7. Close reagent tubes immediately after use in order to avoid contamination.

8. Discard the micropipette tip after pipetting.

9. GENOMICA is not responsible for the results obtained with the kit if other samples different to the ones indicated are used.

5.2. Precautions for the extraction and addition of extracted material to the amplification tube

1. Always wear gloves
2. Clean working surfaces of cabinets with a 10% diluted bleach solution.
3. Turn on the laminar flow and UV light at least 20 minutes before extraction. Turn off the UV light when it is working inside the cabinet.
4. The preparation of the samples before extraction must be made inside the cabinet.

5.3 Precautions for visualization

1. Avoid the pipette tip or the vacuum system touching the bottom of the well, since this could damage the probes printed at the well's bottom.
2. It is recommended to add all solutions to the wall of the CS well; never directly at the bottom.
3. It is convenient not to add the SH solution (hybridization solution) until the denatured products of PCR are ready.
4. The array must not remain dry.
5. Following incubation with the CJ solution, it is very important to wash the microarray thoroughly in order to avoid any residues that could react with the RE solution, resulting in a non-specific precipitation that could lead to false interpretations of the result.
6. Avoid foaming when adding any reagent.
7. When visualizing the image in the reader, ensure that position markers appear and that there are no bubbles, fibers or spots interfering with the reading. Otherwise, clean the outer face of the well with cellulose paper.

6.-SAMPLES

The *CLART® STIs A* kit has been designed and validated to be used with DNA extracted from urine and swabs (anal, vaginal, endo-cervical, urethral and faringeal). GENOMICA is not responsible for the results obtained if other types of samples are used.

Store samples at 4°C always being processed in a time less than 48h. Otherwise, stored frozen at -20°C.

7.-WORKING PROTOCOL

7.1. Extraction of genetic material

7.1.1 Manual extraction of genetic material

Preparation procedures before starting the extraction

- Dissolve Proteinase K in BP before use, in order to reach a concentration of 20 mg/ml. The volume of BP required, is indicated on the bottle of Proteinase K. Once the Proteinase K is dissolved, it must be stored at -20°C, at which Temperature it will be stable for at least 6 months.
- Buffer B5 preparation: Add 96-100% ethanol to the Buffer B5 bottle before use. The volume of ethanol should be used, is indicated on the bottle.
- Heat solution BE to 70°C before use.
- All centrifuging should be performed at room temperature unless otherwise stated.

Warning: Solutions B3 and BW contain guanidine hydrochloride. The use of gloves, glasses and laboratory clothing is recommended when handling.

Sample preparation

Swabs:

- If the swab is conserved in dry medium, add 2ml saline buffer (0.9% NaCl) to the tube containing the swab and agitate vigorously with a vortex for 1 min. Take 1 ml of the sample to a sterile 1.5 ml tube and other 1 ml of the same sample to the other sterile 1.5 ml tube

Note: The sample volume needed for manual extraction is 2 ml, so each sample will have to be processed in parallel in two 1.5 ml microcentrifuge tubes. Each tube with 1 ml of sample will be processed in parallel since Step 1 to Step 5 of the Manual Extraction Protocol, after that the two tubes will be joined in the same purification column.

- If the swab is conserved in liquid medium, take 2 ml of the sample. Take 1ml into a sterile 1.5 ml tube and the other 1ml into another sterile 1.5 ml tube

Note: The sample volume needed for manual extraction is 2 ml, so each sample will have to be processed in parallel in two 1.5 ml microcentrifuge tubes. Each tube with 1 ml of sample will be processed in parallel since Step 1 to Step 5 of the Manual Extraction Protocol, after that the two tubes will be joined in the same purification column.

Urine sample:

Agitate vigorously the sample container and take 2 ml of the sample. Transfer 1ml of the sample into 1.5 ml microcentrifuge tube and the other 1 ml of the sample into the other 1.5 ml microcentrifuge tube .

Note: The sample volume needed for manual extraction is 2 ml, so each sample will have to be processed in parallel in two 1.5 ml microcentrifuge tubes. Each tube with 1 ml of sample will be processed in parallel since Step 1 to Step 5 of the Manual Extraction Protocol, after that the two tubes will be joined in the same purification column.

Manual extraction protocol

1. Centrifuge the samples for 10 min in a microcentrifuge at 12,000 rpm and remove all the liquid with a micropipette. Be careful not to remove the precipitate.
2. Resuspend the precipitate in 180 μ l Solution T1. Transfer to a sterile 1.5 ml microcentrifuge tube.
3. Add 25 μ l of proteinase K solution and mix it all in a vortex. Incubate the samples at 56°C for 1 hour in a thermomixer (with agitation) until the sample is completely lysed. Vortexing samples every 15 minutes for a few seconds will accelerate lysis.
4. After lysis, add 200 μ l of solution B3 to each sample. Mix the samples thoroughly by vortexing them and incubate them at 70°C for 10 min.
5. Add 210 μ l of 96% ethanol to each sample and vortex them immediately.

Note: Do not discard any white precipitate that might form after adding the ethanol. Along with the rest of the solution, this precipitate should be added to the purifying column in the next step.

6. Place a purifying column into a 2 ml collection tube for each sample. Add the first tube of the samples into the purifying column

Note: In this step, one of the tubes of the same sample processed in parallel since Step 1 to Step 5 are added to the purification column

Centrifuge at 12,000 rpm for 1 min. Make sure that all the solution has completely overpassed the membrane and discard the filtered solution and the 2 ml collection tube.

7. Place the purifying column in a new 2 ml collection tube. Add the second tube of the sample (processed in parallel) into the purifying column

Note: The two tubes of the same sample were processed in parallel since Step 1 to Step 5. In this step, both are joined in the same purification column.

Centrifuge at 12,000 rpm for 1 min. Make sure that all the solution has completely overpassed the membrane and discard the filtered solution and the 2 ml collection tube.

8. Place the purifying column in a new 2 ml collection tube and add 500 μ l of Solution BW to the column and centrifuge at 12,000 rpm for 1 min. Dispose the filtered solution and the 2 ml collection tube.

9. Place the purifying column in a new 2 ml collection tube and add 600 µl of Solution B5 to the column and centrifuge at 12,000 rpm for 1 min. Dispose the filtered solution and the 2 ml collection tube.

10. Place the purifying column in a new 2 ml collection tube and centrifuge once more at 12,000 rpm for 1 min in order to eliminate any remaining Solution B5.

Note: Any residual ethanol from Solution B5 might inhibit the required enzymatic reactions; it must therefore be completely eliminated by centrifugation.

11. Place the purifying column in a sterile 1.5 ml microcentrifuge tube. Add 25 µl of Solution BE (pre-heated at 70°C) and incubate for 3 minutes this solution in the column.

Note: Be careful to add the 25 µl of Solution BE into the center of the membrane of the column. .

Centrifuge for 1 minute at 12.000 rpm .Recover the filtrate (approximately 25 µl) in the microcentrifuge tube .Store the rest at –20°C. Store the extracted DNA at -20°C.

7.1.2. Automatic extraction in the NucliSENS™ EasyMag DNA of Biomerieux

- **For swab samples**, if the preservation medium of the swabs is liquid, take 1 ml of the sample for DNA extraction. If it is stored in dry medium add 1.5 ml of saline solution (0.9% sodium chloride) to the tube containing the swab and vortex vigorously for 1 minute. Load 1 ml for DNA extraction.
- **For urine samples**, shake the container and load 1ml of the sample for DNA extraction.
- **In all the cases:** transfer 1 ml of sample to the extractor.
- For each series of samples to be analyzed, an extraction negative control (0.9% sodium chloride) must be included to verify that the samples have not been contaminated during the extraction, amplification and visualization processes, which might lead to a false positive result.
- Use the internal lysis and the “Generic” protocol following the instructions provided by the manufacturer of the NucliSENS™ EasyMag DNA of Biomerieux automatic extractor. The elution volume must be 25 µl.

If another extraction system is used, the elution volume should be optimized in the range of 20-30 µl.

7.2. Amplification reaction

Amplification-specific recommendations:

- Work in the **pre-PCR area**, always using a cabinet and following the recommendations mentioned in section 5.1.
- DNA always adds in cabinet and following the recommendations mentioned in section 5.1. During the process, keep tubes separate and refrigerated.

1. Thaw an amplification tube (white) for each sample to analyze. Keep on ice and not use temperatures above 37°C for thawing.
2. Centrifuge the amplification tubes for a few seconds, so that all liquid can get to the bottom of the tubes (in case you don't have microcentrifuge adaptors available for the tubes, you can use larger tubes after having cut their cap off).
3. Add 5 µL of the extracted DNA to every amplification tube and mix several times with the micropipette. Keep the tubes refrigerated at any time.
4. Program the following temperature cycles on the thermocycler:

1 cycle	95°C 15 min
45 cycles	95°C 30 sec
	63°C 60 sec
	72°C 60 sec
1 cycle	72°C 10 min
4°C continuously until tube collection (optional)	

5. Start the program and place the tubes in the thermocycler when the block has exceeded 90°C. This way, possible unspecified amplifications due to incubation below hybridization temperature are minimized.

7.3. Visualization of the product amplified in CLART-Strip® (CS)

Specific recommendations before starting visualization:

THE PROTOCOL DESCRIBED BELOW SHOULD ALWAYS BE PERFORMED IN THE **POST-PCR AREA**. DO NOT TAKE THE AMPLIFIED PRODUCT IN THE PRE-PCR AREA.

1. Turn on the CAR® (CLINICAL ARRAY READER) before starting the whole procedure. The self-calibration of the equipment takes a few minutes, and it is also necessary to introduce the name of the samples in the program before the reading.
2. Make sure that, before the hybridization begins, the thermomixer temperature has reached the 56°C for at least 1 hour.
3. Warm up the SH (hybridization solution) in the thermomixer.

4. Prepare fresh wash solution before each assay; do not reuse previously prepared solutions or residues.
5. Use filtered tips different for each well and change it every time a reagent is added.
6. In case of using vacuum pumps equipped with 8-tip comb for aspirating solutions, discard the combs after each use or decontaminate them with a 10% diluted bleach solution after every assay. Make sure the pump aspirates properly and does not leave traces at the bottom of the well.
7. Aspirate the different solutions completely without touching the array.

7.3.1. Manual visualization

1. Denaturation:

Place the amplification tubes in the thermocycler when this has reached 95°C and incubate the tubes for 10 min. Not to exceed 10 min time of denaturation to prevent the tubes are opened and contamination may occur.

Remove the tubes from the 95°C incubation and place them immediately on ice.

2. Diluted TL solution preparation:

For each CS strip (a total of 8 wells), prepare 10 mL of diluted wash solution by adding 1 mL of TL solution to 9 mL of distilled water, gently stir.

3. Prewash of the CS:

Before beginning the assay, it is necessary to wash the strips by adding 200 µL of diluted TL solution to each well. Mix it with the multichannel pipette 10 to 15 times, taking into account that the surface of the array must not be touched. **It is advised to carry out this wash while the amplified samples are being denatured and maintain the wash solution in the well until samples are going to be added.** Discard the diluted TL solution with a pipette, or preferably with a vacuum pump.

The array must be free from solution residues, although it must never remain dry. Add the next solution immediately.

4. Hybridization:

Before using the SH solution, it must be heated at 56°C until the complete dilution of the salts. Once the PCR products have been denatured, add 100 µL of SH solution (prevent foaming) to each CS well. Next, add 5 µL of denatured PCR product from amplification tube. Use one array per sample.

Mix it several times, being careful not to touch the bottom of the well. It is recommended to load each strip independently and separately from the rest to avoid contaminations. Cover the microtiter plate with the plastic lid provided and incubate in the thermomixer for **1 hour at 56°C, shaking at 550 rpm.**

After this incubation, remove the plate from thermoshaker and aspirate the SH solution of the CS with a pipette or, preferably, with a vacuum pump: The array must be free from solution residues, although it must never remain dry. Add the next solution immediately. After incubation set the thermomixer at 30°C, and in motion, so it may be used later in step 6.

5. Double Wash:

Add 200 µL of diluted TL solution to each CS well, resuspend 10 to 15 times with the multichannel pipette. Discard the diluted TL solution with a pipette, or preferably with a multichannel vacuum pump without leaving any residues. **Repeat the procedure. This step must be carried out with different tips for each well in both washes.** If having arrived at this step, the thermomixer has not reached 30°C, the wells are left with TL solution until the thermomixer reaches the temperature.

6. Blocking and conjugate:

It is recommended to centrifuge the high-affinity CJ solution for 10 seconds before use. Then, prepare the diluted CJ solution as follows: for each CS strip, mix **1 mL of DC solution** and **7.5 µL of high-affinity CJ solution**.

Discard the diluted TL Solution without leaving any residues of the solution and add 100 µL of diluted CJ solution to each CS well. Incubate for **15 exact minutes in the** thermoshaker at **30°C, shaking at 550 rpm**. After this incubation, remove the plate and discard the solution rapidly with a pipette or a multichannel vacuum pump. Once finished the incubation, set the thermomixer at 25°C, and in motion, so it may be used later in step 8.

7. Triple Wash:

Add immediately 200 µL of diluted TL solution to each CS well, mixing it 10 to 15 times with the multichannel pipette and discard the solution completely with the pipette or vacuum pump. **Repeat the procedure two more times.**

It is **very important** to avoid any residues of the CJ solution, since they could react with the RE Solution generating an unspecified signal.

8. Development with RE solution: Remove the diluted TL solution completely and add 100 µL of RE solution to each CS well and incubate for **10 minutes at 25°C** in the thermomixer **without shaking**.

Warning! It is very important to use the thermomixer without shaking.

9. Discard the complete TL solution using a pipette or a vacuum system. The array must remain dry for the reading.

10. CAR® (CLINICAL ARRAY READER): place the plate normally on the tray and the CAR® will take and analyse the arrays automatically.

7.3.2. autoclart® visualization

1. Denaturation:

Place the amplification tubes in the thermocycler when this has reached 95°C and incubate the tubes for 10 min. the tubes from the 95°C incubation and place them immediately on ice.

2. Switch on the autoclart® unit and follow the instructions described on the screen :

1. Close the door and press the knob.
2. Select Run at the main menu.
3. Select the assay **STIs Test.** among those listed.
4. Select the well of the strip where run should start: A1 or E1 in case the first 4 wells have been already processed.
5. Select the amount of samples to be processed.
The autoclart® allows to process from 4 up to 96 samples per run. In any case, samples should be always multiples of four.
6. Confirm the number of samples and start up well (A1 or E1) are correct.
7. Place the tips rack (full) on its position.
8. Check that both, tip waste and liquid waste containers are empty.
9. Fill the bottle with 250 ml distilled water.
10. Add each reagent to its specific container. autoclart® calculates the specific volumes required according to the amount of samples indicated:
 - **TL** (Washing buffer). Volume showed in the display indicates the diluted washing buffer required. In order to prepare the diluted washing buffer please dilute the TL reagent provided 1:10 into distilled water.
 - **SH** (Hybridization solution). It is provided ready to use. Add the specified volume in the container once tempered.
 - **CJ** (Conjugate). It's recommended to shortly spin the CJ before use. Display shows final volume of diluted CJ, meaning that each mL indicated on the display should be prepared as follows: 1 ml of DC (Conjugate Diluent) and 7,5 µl CJ reagent. Vortex the diluted solution in order to mix it properly up.
 - **RE** (Developer). Add the RE volume indicated on the display.
11. Close the door and press the knob.

The device will start priming the system and cleaning the tips with water. Then it will perform the pre-washes of the CS and adding the hybridization solution. Once finished these steps, the device will beep as a signal for pipetting the samples on their specific CS. autoclart® will automatically stop beeping as soon the user opens the door.

12. For adding the samples on the CSs, please remove the plate carefully from autoclart® unit and add **5µl** of the denatured product from the green tube and **5µl** of the denatured product from the blue tube respectively to each well. Mix it up carefully in order not to touch the array and place the microplate again on the autoclart®. Press the knob again to continue the visualization process.

13. Once finished the visualization process, the autoclart® unit will beep indicating the end of the run. Please remove the microplate carefully and proceed with the reading step on the CAR®.

WARNING: Once the automatic visualization phase is finished , it is important to read the results immediately in the CAR®, otherwise, false negatives may appear due to the loss of the sign .

14. CAR® (CLINICAL ARRAY READER): place the plate normally on the tray and the CAR® will take and analyse the arrays automatically.

8. READING OF THE RESULTS

The processing of data obtained from each analysis is carried out automatically. The reading and analysis system (CAR®) will provide a report indicating the results.

The monitor displays a table with two columns; in the left column lists the species that are characterized in the array. In the right column lists the analytical result: positive, negative, inconclusive, without DNA or inhibited.

9. INTERPRETATION OF THE RESULTS

One of the main drawbacks of genomic amplification is the utilization of poor quality DNA samples (for taking insufficient amount of sample, DNA degradation due to an incorrect storage of the sample, loss of DNA of the sample during extraction) or the presence of DNA polymerase inhibitors in the samples to be analyzed, thus interfering with the genomic amplification and resulting in false negatives.

With the **CLART® STIs A kit**, the false negatives are removed by adding an internal control in the amplification tube, which is indicative of the efficiency of the amplification reaction. Also it is included in the tube a genomic DNA extraction control to detect false negatives due to failures in the extraction.

In every set of analysis a negative extraction control should be included to check that samples have not been contaminated during the extraction, amplification and visualization, thus giving rise to a false positive.

The amplification tube contains the following amplification primers:

- A pair of oligonucleotides that amplify a fragment of the human CFTR gene as a genomic DNA control of the patient.
- A pair of oligonucleotides that amplify a modified plasmid included in the amplification tube, which is used as amplification control of the PCR reaction.
- Specific oligonucleotides for the targets of the pathogens to be detected.

The reaction tube has been designed in order to favour the amplification of microorganisms comparing to the other two controls. Among these two controls, the amplification of the genomic DNA will be performed preferentially comparing to the control of the amplification reaction.

The reason for this design is:

Genomic DNA control would only be essential for confirming a negative result, since it informs you that the DNA extraction from stool sample was conducted successfully, even if there was no amplification of pathogen

PCR control would only be essential when no amplification in the tube is found, because it will help to distinguish between an inhibited PCR and a sample where no DNA is present.

There are two possibilities that may lead to a not valid result:

- Presence of inhibitors in the sample, in which case there would be repeated from extraction.
- Fault in the amplification tube, in which case there would be repeated from the amplification.

There are two possibilities that may lead to an inconclusive result, in which case there would be repeated from the visualization.

- In those cases when replicates of an array probe are very different from each other.
- When the signal intensity of non-normalized absorbance is found at the detection limit of the technique, which range is set by the software for each type of microorganism.

10. TECHNICAL AND OPERATIONAL SPECIFICATIONS

10.1 Control of known interferences:

False negatives are one of the drawbacks in the detection by genomic amplification due to either, an inadequate quality of the extracted DNA (due to insufficient sample quantity, DNA degradation, inadequate storage or DNA loss during extraction) or to the presence of DNA polymerase inhibitors in the samples that are to be processed (alcohol, salts, etc.).

To avoid these interferences, the indications appearing in the sections 5, 6 and 7 of this manual must be followed.

10.2 Technical specifications:

Processing parameters:

Analytical sensitivity. Analytical sensitivity has been determined by the amplification of serial dilutions of recombinant plasmids for each one of the mutations detected by the kit. Each one of them has the amplified product inserted (including the part that is complementary to the specific detection probes). The visualisation was done in CS, giving rise to the following results (Table 1):

Microorganism	Copies/5 ul
<i>Neisseria gonorrhoeae</i>	10²
<i>Chlamydia trachomatis</i> NLGV	
<i>Mycoplasma genitalium</i>	
<i>Trichomonas vaginalis</i>	
<i>Chlamydia trachomatis</i> LGV	10
<i>Chlamydia trachomatis</i> generic	

Table 1. Relationship of the number of copies of recombinant plasmid necessary to obtain a sensitivity of 100% in the detection of each one of the microorganisms.

Analytical specificity. Specificity experiments were carried out in recombinant plasmids observing that an unspecific detection of other microorganisms different to what is sought to be determined is not produced. Therefore, it is considered that the technique reaches an analytical specificity of 100%.

Diagnostic utility parameters:

In order to determine the diagnostic parameters of the kit, a comparative assessment of the **CLART® STIs A** kit was carried out against the reference techniques culture or PCR. For this evaluation, we collaborated with the following laboratories:

- Department of Microbiology, Trías i Pujol University Hospital, Badalona, Spain.
- OpenHouse Medical Centre, Madrid, Spain.
- Monte Naranco Hospital, Oviedo, Spain.
- Sandoval Sanitary Center, Madrid, Spain.
- Virgen de la Macarena Hospital, Sevilla, Spain

The presence of each one of the microorganisms that were detected with the kit was analyzed from genetic material of urine and swab samples. We analyzed a total of 326 samples: 49 urine samples and 277 swabs samples. The organisms tested are described in Table 2.

For each sample, the result was considered true if there is concordance between the reference technique and the **CLART® STIs A** technique. The discrepancies between the two techniques were resolved as follows:

- A positive result for the gold standard and negative result for **CLART® STIs A**: the reference technique is considered like correct data, and it is considered false negative for **CLART® STIs A**.
- A negative result for the reference technique and a positive result for **CLART® STIs A**: the discrepancy will be discussed by Nested-specific PCR and sequencing. The result is what is considered as true.

Table. 2. Diagnostic sensitivity and specificity of CLART® STIs A for each microorganism in urine samples.

N = 49*	VP	VN	FP	FN	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
<i>Chlamydia trachomatis</i>	40 CTgeneric.:1 LGV:1 NLGV: 38	9	0	0	100	100	100	100
<i>Neisseria gonorrhoeae</i>	8	41	0	0	100	100	100	100
<i>Mycoplasma genitalium</i>	8	40	1	0	100	88.9	100	97.6
<i>Trichomonas vaginalis</i>	0	49	0	0	–**	100	100	–**

CT: *Chlamydia trachomatis*

LGV: *Chlamydia trachomatis* producers of lymphogranuloma venereum

NLGV: *Chlamydia trachomatis* no producers of lymphogranuloma venereum

VP: True positive , VN: True negative, FP: False positive ,FN: False negative

*The number of samples analysed does not match the number of micro-organisms analyzed, since in these 49 samples are available, there are some negative, mono-infection samples and samples with co-infection of 2 or more microorganisms.

***Trichomonas vaginalis* in urine is not present so it has not been possible to analyze samples positive for this mo. The detection is specific for the microorganisms given that not to appear false positive.

Table. 3. Diagnostic sensitivity and specificity of CLART® STIs A for each microorganism in swabs samples.

N = 277*	VP	VN	FP	FN	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
<i>Chlamydia trachomatis</i>	42 CT.: 8 LGV: 4 NLGV: 30	234	0	1**	97.7	100	100	99.6
<i>Neisseria gonorrhoea</i>	49	226	1	1***	98	99.6	98	99.6
<i>Mycoplasma genitalium</i>	6	270	0	1**	85.7	100	100	99.6
<i>Trichomonas vaginalis</i>	53	223	0	1	98.1	100	100	99.6

CT: *Chlamydia trachomatis*

LGV: *Chlamydia trachomatis* producers of lymphogranuloma venereum

NLGV: *Chlamydia trachomatis* no producers of lymphogranuloma venereum

VP: True positive , VN: True negative, FP: False positive ,FN: False negative

*The number of samples analysed does not match the number of micro-organisms analyzed, since in these 277 samples are available, there are some negative, mono-infection samples and samples with co-infection of 2 or more microorganisms.

**Unable to confirm the presence of the organism in the sample with Nested-PCR and / or specific PCR.

***Positive sample for sequencing *Neisseria flava*

Diagnostic specificity:

The technique has been validated with urine and swabs samples both negative and positive for other microorganisms not included in the kit, and the results show no cross-reaction with them.

Reproducibility and diagnostic repeatability by sample type.

The reproducibility and diagnostic repeatability was processed from sample extraction to visualization in CS.

	%
--	---

Urines	
Repeatability (n=6)	100
Reproducibility (n=8)	100
Swabs	
Repeatability (n=41)	99.2
Reproducibility (n=46)	97.1

11. BIBLIOGRAPHY

1. “*Gardnerella, Trichomonas vaginalis, Candida, Chlamydia trachomatis, Mycoplasma hominis* and *Ureaplasma urealyticum* in the genital discharge of symptomatic fertile and asymptomatic infertile women”. Erminia Casari, Antonella Ferrario, Emanuela Morengi, Alessandro Montanelli. *New Microbiologica*, 33, 69-76, 2010.
2. “Global strategy for the prevention and control of sexually transmitted infections: 2006 - 2015 : breaking the chain of transmission”. WHO
3. “Sexually Transmitted Diseases in the United States, 2008 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis” CDC.
4. “Persistent increase in the incidence of acute male urethritis diagnosed in general practices in France”. *Véronique Massari, Yves Dorléans and Antoine Flahault*. *British Journal of General Practice* 2006; 56: 110–114.
5. “*Mycoplasma genitalium* presence, resistance and epidemiology in Greenland” Dionne C. Gesink, Gert Mulvad, Ruth Montgomery-Andersen, Upaluk Poppel, Stephan Montgomery-Andersen, Aka Binzer, Lee Vernich, Gillian Frosst, Flemming Stenz, Elizabeth Rink, Ove Rosing Olsen, Anders Koch and Jørgen Skov Jensen. *Int J Circumpolar Health* 2012, 71: 18203